Developer docs
API playgroundTry for free, no card

Search company profiles

ABK Biomedical

Full company profile

uuid000241g

Namestring
ABK Biomedical
Legal namestring
ABK Biomedical Inc.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

ABK Biomedical is a clinical-stage medical device company headquartered in Halifax, Nova Scotia, founded in 2012 as a spin-out from Dalhousie University by Daniel Boyd and Sharon Kehoe. The company develops proprietary glass-based embolic and radioembolic microspheres for interventional oncology, with two core products: Eye90 microspheres, an investigational Yttrium-90 (Y-90) radioembolization therapy for liver cancer (notably hepatocellular carcinoma) currently advancing through the Route90 pivotal Phase III FDA IDE trial; and Easi-Vue embolic microspheres, which holds FDA 510(k) clearance. Eye90 incorporates a differentiated dual-syringe delivery system and is supported by an FDA Breakthrough Device Designation granted in 2023, positioning the product for an accelerated PMA pathway.

The company is pre-commercial on its lead asset. Its business model centers on eventual direct sale of single-use microsphere devices and配套 delivery systems to hospital-based interventional radiology and oncology departments, supplemented by long-term isotope supply partnerships. To secure commercial readiness, ABK has formalized a long-term Y-90 supply agreement with the University of Missouri Research Reactor (MURR)—the sole U.S. producer of Yttrium-90—and is constructing a GMP manufacturing facility in Ashland, Missouri with COR Development, alongside building a U.S. field sales presence. The company is ISO 13485 certified and operates with 11–50 employees, led by CEO Michael Mangano, CMO Aravind Arepally, M.D., and CCO Gary Donofrio.

ABK has raised approximately $140M CAD (over $100M USD) across multiple rounds, including a $30M Series C (Dec 2022, Santé Ventures lead) and a $35M Series D (Oct 2025, J.P. Morgan Life Sciences Private Capital lead). The Route90 pivotal trial completed enrollment of 120 patients across 20 international sites in February 2026, setting up a near-term PMA submission. The strategic posture is that of a late-clinical-stage device company transitioning toward U.S. commercialization with secured isotope supply and dedicated manufacturing capacity.

Short descriptiontext

ABK Biomedical is a clinical-stage medical device company developing proprietary glass-based Y-90 radioembolization microspheres (Eye90) and embolic microspheres (Easi-Vue) for interventional oncology treatment of liver cancer patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHalifax, Canada
HQ citystring
Halifax
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
embolic microspheres, Y90 radioembolization devices, interventional oncology devices, liver cancer treatment, imageable medical devices
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Interventional Oncology Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Eye90 microspheres (pre-commercial)
TypeOne Time License
Description

ABK Biomedical is a clinical-stage company developing Eye90 microspheres for Y90 radioembolization of liver tumors. The product is not yet FDA-approved and is currently only available through clinical trials. Revenue will be generated upon FDA approval and commercialization, likely through direct hospital/health system sales.

prnewswire.com
2Easi-Vue embolic microspheres (FDA 510(k) cleared)
TypeOne Time License
Description

Easi-Vue has received FDA 510(k) clearance for embolization of arteriovenous malformations and hypervascular tumors, representing the company's only commercially available product as of the data period.

abkbiomedical.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Eye90 microspheres®
Description

A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization. FDA-designated breakthrough technology for liver cancer treatment.

abkbiomedical.com
+1 more record
Core offering1 text field

ABK Biomedical develops and manufactures imageable embolic microsphere technologies for interventional oncology. Its portfolio includes Eye90 microspheres, an investigational Yttrium-90 radioembolization product designed for liver cancer treatment with CT-visualizable precision dosimetry, and Easi-Vue embolic microspheres, an FDA 510(k) cleared bland embolization device. The proprietary radiopaque glass composition allows clinicians to directly visualize embolic distribution under CT, fluoroscopy, and ultrasound imaging.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 120 patients enrolled across 20 international sites in Route90 pivotal Phase III FDA IDE study (largest prospective FDA IDE trial for Y90 radioembolization of HCC)
+2 more records
Product overview1 text field

ABK Biomedical is a clinical-stage medical device company developing a portfolio of imageable embolic microsphere technologies for interventional oncology. The product portfolio consists of two distinct products: Eye90 microspheres® (an investigational Y90 radioembolization device for liver cancer treatment currently undergoing FDA IDE pivotal trials) and Easi-Vue™ embolic microspheres (an FDA 510(k)-cleared imageable bland embolization product). Both products leverage proprietary radiopaque glass composition technology enabling physician visualization during procedures via CT imaging. The company is headquartered in Halifax, Nova Scotia, with operations in Ladera Ranch, California.

Product and service2 records
1Eye90 Microspheres
CategoryY90 Radioembolization Devices
Description

Investigational Yttrium-90 radioembolization microspheres designed for liver cancer treatment, featuring proprietary radiopaque glass composition that enables CT-based precision dosimetry and direct visualization of microsphere distribution. The dual-syringe administration system allows smaller-diameter delivery for deeper tumor penetration. Indicated for interventional oncology procedures treating hepatocellular carcinoma and metastatic liver cancer.

2Easi-Vue Embolic Microspheres
CategoryBland Embolization Devices
Description

FDA 510(k) cleared bland embolization microspheres indicated for transarterial embolization procedures. The proprietary radiopaque glass composition enables multi-modality imaging visibility under CT, fluoroscopy, and ultrasound, allowing clinicians to directly visualize embolic distribution following deployment. Used by interventional radiologists and interventional oncologists for embolization of hypervascular tumors.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Missouri University Research Reactor (MURR)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Long-term partnership agreement naming MURR as the primary irradiation partner for Eye90 microspheres. MURR is currently the only location in the United States producing Y-90 for clinical and commercial use. The partnership formalizes seven years of collaboration and secures a reliable, scalable production partner as ABK transitions toward commercialization.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Strategic partnership to develop a state-of-the-art GMP manufacturing facility in Ashland, Missouri (Cartwright Business Park) dedicated to commercial-scale production of Eye90 microspheres. COR Development is developing the facility infrastructure. This represents a core partnership for long-term commercial manufacturing capacity.

Strategic tierMinorTypeOthersAnnounced on2025-10-14
Description

Construction firm overseeing the design and construction of the GMP manufacturing facility in Ashland, Missouri at Cartwright Business Park.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for First-in-Dog (FIDO) HCC study evaluating Eye90 microspheres treatment in canine patients with hepatocellular carcinoma, generating preclinical/clinical evidence for the technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Founding institution and research partner. ABK Biomedical was founded at Dalhousie University in 2012 and maintains ongoing research collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner collaborating on clinical studies and data analysis for Eye90 microspheres technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner that collaborated with ABK to develop a novel hepatic tumor microvascular model for evaluating Y90 microsphere deposition characteristics.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research partner involved in scientific research and clinical studies for Eye90 microspheres.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical research organization partner providing clinical development expertise.

10Sarah Cannon Research Institute (SCRI)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-principal investigators from HCA Healthcare Sarah Cannon Cancer Network lead the Route90 pivotal trial, contributing to clinical study design and execution.

abkbiomedical.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner providing regulatory and compliance consulting services.

12Paragon Medical
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Development partner contributing to product development and manufacturing processes.

abkbiomedical.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Development partner contributing to product development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GE HealthCare is a dominant imaging equipment vendor (CT, fluoroscopy, PET/CT) used with Eye90 for both delivery visualization and dosimetry. While not a direct microsphere competitor, it is a critical ecosystem participant and adjacent incumbent.

TypeEmerging player
Description

AngioDynamics develops NanoKnife and other interventional oncology and embolization products. Smaller than the Y90 microsphere incumbents but a relevant peer in the interventional oncology and locoregional treatment space that competes for the same HCC patient population.

TypeDirect peer
Description

Guerbet supplies Lipiodol and other interventional imaging and locoregional oncology products, competing in interventional radiology procedures for HCC. Same end users and same procedural workflow competition.

TypeBroad incumbent
Description

Varian is a radiation oncology incumbent (and prior ABK investor) offering a broad portfolio spanning external beam radiotherapy, proton therapy, and software. They have historically commercialized SIR-Spheres via their acquisition of BTG/Biocompatibles, making them a channel-relevant incumbent.

5Cook Medical
TypeDirect peer
Description

Cook Medical offers a broad embolization product portfolio used by interventional radiologists, including microsphere and occlusion products that overlap with ABK's Easi-Vue. Direct overlap in interventional oncology procurement decisions.

TypeDirect peer
Description

Merit Medical markets a portfolio of embolization, tumor ablation, and interventional oncology devices. Comparable procedural call points and indications (liver embolization), and a likely competitive overlap with both Eye90 and Easi-Vue.

TypeDirect peer
Description

Sirtex markets SIR-Spheres Y-90 resin microspheres, the principal direct competitor to ABK's Eye90 in Y90 radioembolization for liver tumors. Comparable patient indication, delivery modality, and purchaser base (interventional oncology).

TypeDirect peer
Description

Penumbra is a leading interventional device company developing embolization, thrombectomy, and interventional oncology products. Comparable customer base (interventional radiologists) and adjacent product categories in imageable/targeted embolization.

TypeBroad incumbent
Description

Boston Scientific owns TheraSphere, the only other Y-90 glass microsphere product on the market. ABK's imageable Eye90 is differentiated structurally from TheraSphere, but they compete head-to-head for the same physician customers and HCC/mCRC indications.

TypeEmerging player
Description

Terumo distributes QuiremSpheres (holmium-166 microspheres) in Europe, a directly analogous radioembolization product targeting similar liver tumor indications. Different isotope, same procedural channel and call point, positioning it as an emerging alternative.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ABK Biomedical

Interventional Oncology Medical Devicesabkbiomedical.com

ABK Biomedical is a clinical-stage medical device company developing proprietary glass-based Y-90 radioembolization microspheres (Eye90) and embolic microspheres (Easi-Vue) for interventional oncology treatment of liver cancer patients.

What ABK Biomedical does

ABK Biomedical is a clinical-stage medical device company headquartered in Halifax, Nova Scotia, founded in 2012 as a spin-out from Dalhousie University by Daniel Boyd and Sharon Kehoe. The company develops proprietary glass-based embolic and radioembolic microspheres for interventional oncology, with two core products: Eye90 microspheres, an investigational Yttrium-90 (Y-90) radioembolization therapy for liver cancer (notably hepatocellular carcinoma) currently advancing through the Route90 pivotal Phase III FDA IDE trial; and Easi-Vue embolic microspheres, which holds FDA 510(k) clearance. Eye90 incorporates a differentiated dual-syringe delivery system and is supported by an FDA Breakthrough Device Designation granted in 2023, positioning the product for an accelerated PMA pathway.

The company is pre-commercial on its lead asset. Its business model centers on eventual direct sale of single-use microsphere devices and配套 delivery systems to hospital-based interventional radiology and oncology departments, supplemented by long-term isotope supply partnerships. To secure commercial readiness, ABK has formalized a long-term Y-90 supply agreement with the University of Missouri Research Reactor (MURR)—the sole U.S. producer of Yttrium-90—and is constructing a GMP manufacturing facility in Ashland, Missouri with COR Development, alongside building a U.S. field sales presence. The company is ISO 13485 certified and operates with 11–50 employees, led by CEO Michael Mangano, CMO Aravind Arepally, M.D., and CCO Gary Donofrio.

ABK has raised approximately $140M CAD (over $100M USD) across multiple rounds, including a $30M Series C (Dec 2022, Santé Ventures lead) and a $35M Series D (Oct 2025, J.P. Morgan Life Sciences Private Capital lead). The Route90 pivotal trial completed enrollment of 120 patients across 20 international sites in February 2026, setting up a near-term PMA submission. The strategic posture is that of a late-clinical-stage device company transitioning toward U.S. commercialization with secured isotope supply and dedicated manufacturing capacity.

ABK Biomedical firmographics

Firmographics
Name
ABK Biomedical
Legal name
ABK Biomedical Inc.
Website
https://abkbiomedical.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
ABK Biomedical is a clinical-stage medical device company developing proprietary glass-based Y-90 radioembolization microspheres (Eye90) and embolic microspheres (Easi-Vue) for interventional oncology treatment of liver cancer patients.
Ownership category
akta.pro rank

ABK Biomedical industry classification

Industry
Product category
Interventional Oncology Medical Devices
NAICS
Irradiation Apparatus Manufacturing (334517), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • Embolic microspheres
  • Y90 radioembolization devices
  • Interventional oncology devices
  • Liver cancer treatment
  • Imageable medical devices

Where ABK Biomedical is headquartered

Location

Headquarters

HQ city
Halifax
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

ABK Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Eye90 microspheres (pre-commercial): ABK Biomedical is a clinical-stage company developing Eye90 microspheres for Y90 radioembolization of liver tumors. The product is not yet FDA-approved and is currently only available through clinical trials. Revenue will be generated upon FDA approval and commercialization, likely through direct hospital/health system sales.
  2. Easi-Vue embolic microspheres (FDA 510(k) cleared): Easi-Vue has received FDA 510(k) clearance for embolization of arteriovenous malformations and hypervascular tumors, representing the company's only commercially available product as of the data period.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

ABK Biomedical product offering

Product offering

Core offering

ABK Biomedical develops and manufactures imageable embolic microsphere technologies for interventional oncology. Its portfolio includes Eye90 microspheres, an investigational Yttrium-90 radioembolization product designed for liver cancer treatment with CT-visualizable precision dosimetry, and Easi-Vue embolic microspheres, an FDA 510(k) cleared bland embolization device. The proprietary radiopaque glass composition allows clinicians to directly visualize embolic distribution under CT, fluoroscopy, and ultrasound imaging.

Product overview

ABK Biomedical is a clinical-stage medical device company developing a portfolio of imageable embolic microsphere technologies for interventional oncology. The product portfolio consists of two distinct products: Eye90 microspheres® (an investigational Y90 radioembolization device for liver cancer treatment currently undergoing FDA IDE pivotal trials) and Easi-Vue™ embolic microspheres (an FDA 510(k)-cleared imageable bland embolization product). Both products leverage proprietary radiopaque glass composition technology enabling physician visualization during procedures via CT imaging. The company is headquartered in Halifax, Nova Scotia, with operations in Ladera Ranch, California.

Differentiator

Problem solved

Functional benefit

Brands

  • Eye90 microspheres®: A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization. FDA-designated breakthrough technology for liver cancer treatment.
  • Easi-Vue™ embolic microspheres

Products and services

  • Eye90 Microspheres Investigational Yttrium-90 radioembolization microspheres designed for liver cancer treatment, featuring proprietary radiopaque glass composition that enables CT-based precision dosimetry and direct visualization of microsphere distribution. The dual-syringe administration system allows smaller-diameter delivery for deeper tumor penetration. Indicated for interventional oncology procedures treating hepatocellular carcinoma and metastatic liver cancer.
  • Easi-Vue Embolic Microspheres FDA 510(k) cleared bland embolization microspheres indicated for transarterial embolization procedures. The proprietary radiopaque glass composition enables multi-modality imaging visibility under CT, fluoroscopy, and ultrasound, allowing clinicians to directly visualize embolic distribution following deployment. Used by interventional radiologists and interventional oncologists for embolization of hypervascular tumors.

Quantifiable outcome

  • 120 patients enrolled across 20 international sites in Route90 pivotal Phase III FDA IDE study (largest prospective FDA IDE trial for Y90 radioembolization of HCC)
  • +2 more outcomes

Companies that use ABK Biomedical

Customer profile

Segments1 record

Ideal customer profiles1 record

ABK Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ABK Biomedical partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Missouri University Research Reactor (MURR)coreStrategic or Co-development Partner · 31 March 2026Long-term partnership agreement naming MURR as the primary irradiation partner for Eye90 microspheres. MURR is currently the only location in the United States producing Y-90 for clinical and commercial use. The partnership formalizes seven years of collaboration and secures a reliable, scalable production partner as ABK transitions toward commercialization.
  • COR DevelopmentcoreStrategic or Co-development Partner · 14 October 2025Strategic partnership to develop a state-of-the-art GMP manufacturing facility in Ashland, Missouri (Cartwright Business Park) dedicated to commercial-scale production of Eye90 microspheres. COR Development is developing the facility infrastructure. This represents a core partnership for long-term commercial manufacturing capacity.
  • Coil ConstructionminorOthers · 14 October 2025Construction firm overseeing the design and construction of the GMP manufacturing facility in Ashland, Missouri at Cartwright Business Park.
  • University of Missouri College of Veterinary MedicineminorStrategic or Co-development PartnerPartnership for First-in-Dog (FIDO) HCC study evaluating Eye90 microspheres treatment in canine patients with hepatocellular carcinoma, generating preclinical/clinical evidence for the technology.
  • Dalhousie UniversityminorStrategic or Co-development PartnerFounding institution and research partner. ABK Biomedical was founded at Dalhousie University in 2012 and maintains ongoing research collaboration.
  • MD Anderson Cancer CenterminorStrategic or Co-development PartnerResearch partner collaborating on clinical studies and data analysis for Eye90 microspheres technology.
  • North Carolina State UniversityminorStrategic or Co-development PartnerResearch partner that collaborated with ABK to develop a novel hepatic tumor microvascular model for evaluating Y90 microsphere deposition characteristics.
  • Northwestern UniversityminorStrategic or Co-development PartnerAcademic research partner involved in scientific research and clinical studies for Eye90 microspheres.
  • Syneos HealthminorStrategic or Co-development PartnerClinical research organization partner providing clinical development expertise.
  • Sarah Cannon Research Institute (SCRI)minorStrategic or Co-development PartnerCo-principal investigators from HCA Healthcare Sarah Cannon Cancer Network lead the Route90 pivotal trial, contributing to clinical study design and execution.
  • ProPharmaminorStrategic or Co-development PartnerResearch partner providing regulatory and compliance consulting services.
  • Paragon MedicalminorStrategic or Co-development PartnerDevelopment partner contributing to product development and manufacturing processes.
  • SandfireminorStrategic or Co-development PartnerDevelopment partner contributing to product development.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

ABK Biomedical competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: GE HealthCare is a dominant imaging equipment vendor (CT, fluoroscopy, PET/CT) used with Eye90 for both delivery visualization and dosimetry. While not a direct microsphere competitor, it is a critical ecosystem participant and adjacent incumbent.
  • Varian (a Siemens Healthineers company): Varian is a radiation oncology incumbent (and prior ABK investor) offering a broad portfolio spanning external beam radiotherapy, proton therapy, and software. They have historically commercialized SIR-Spheres via their acquisition of BTG/Biocompatibles, making them a channel-relevant incumbent.
  • Boston Scientific (TheraSphere): Boston Scientific owns TheraSphere, the only other Y-90 glass microsphere product on the market. ABK's imageable Eye90 is differentiated structurally from TheraSphere, but they compete head-to-head for the same physician customers and HCC/mCRC indications.

Emerging players

  • AngioDynamics: AngioDynamics develops NanoKnife and other interventional oncology and embolization products. Smaller than the Y90 microsphere incumbents but a relevant peer in the interventional oncology and locoregional treatment space that competes for the same HCC patient population.
  • Terumo (QuiremSpheres): Terumo distributes QuiremSpheres (holmium-166 microspheres) in Europe, a directly analogous radioembolization product targeting similar liver tumor indications. Different isotope, same procedural channel and call point, positioning it as an emerging alternative.

Direct peers

  • Guerbet: Guerbet supplies Lipiodol and other interventional imaging and locoregional oncology products, competing in interventional radiology procedures for HCC. Same end users and same procedural workflow competition.
  • Cook Medical: Cook Medical offers a broad embolization product portfolio used by interventional radiologists, including microsphere and occlusion products that overlap with ABK's Easi-Vue. Direct overlap in interventional oncology procurement decisions.
  • Merit Medical Systems: Merit Medical markets a portfolio of embolization, tumor ablation, and interventional oncology devices. Comparable procedural call points and indications (liver embolization), and a likely competitive overlap with both Eye90 and Easi-Vue.
  • Sirtex Medical: Sirtex markets SIR-Spheres Y-90 resin microspheres, the principal direct competitor to ABK's Eye90 in Y90 radioembolization for liver tumors. Comparable patient indication, delivery modality, and purchaser base (interventional oncology).
  • Penumbra: Penumbra is a leading interventional device company developing embolization, thrombectomy, and interventional oncology products. Comparable customer base (interventional radiologists) and adjacent product categories in imageable/targeted embolization.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ABK Biomedical social profiles

Digital presence

ABK Biomedical compliance and trust

Trust signal

Compliance1 record

ABK Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ABK Biomedical leadership team

Management profile

Number of profiles

Profiles5 records

ABK Biomedical funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ABK Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABK Biomedical

What does ABK Biomedical do?

ABK Biomedical develops and manufactures imageable embolic microsphere technologies for interventional oncology. Its portfolio includes Eye90 microspheres, an investigational Yttrium-90 radioembolization product designed for liver cancer treatment with CT-visualizable precision dosimetry, and Easi-Vue embolic microspheres, an FDA 510(k) cleared bland embolization device. The proprietary radiopaque glass composition allows clinicians to directly visualize embolic distribution under CT, fluoroscopy, and ultrasound imaging.

When was ABK Biomedical founded?

ABK Biomedical was founded in 2012. It employs 11 to 50 people.

Where is ABK Biomedical based?

ABK Biomedical is headquartered in Halifax, Canada, in the North America region.

How does ABK Biomedical make money?

Two revenue lines are on record. Eye90 microspheres (pre-commercial) is the primary driver. The others are easi-Vue embolic microspheres (FDA 510(k) cleared).

Who are ABK Biomedical's main competitors?

Broad incumbents on record are GE HealthCare, Varian (a Siemens Healthineers company) and Boston Scientific (TheraSphere). Emerging players are AngioDynamics and Terumo (QuiremSpheres). Direct peers are Guerbet, Cook Medical, Merit Medical Systems, Sirtex Medical and Penumbra.

Does ABK Biomedical have an API?

No public API is recorded for ABK Biomedical.

What industry is ABK Biomedical in?

ABK Biomedical's product category is Interventional Oncology Medical Devices. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooABK Biomedical launches construction on Ashland manufacturing facilityABK Biomedical began construction on a commercial manufacturing facility in Ashland, Missouri, to support production of its liver cancer treatment Eye90 microspheres. The project, completed in 2027, is part of the company's long-term strategy to manufacture at commercial scale.PR NewswireABK Biomedical celebrates construction kickoff of their future homeABK Biomedical marked a construction kickoff for its future commercial manufacturing facility in Ashland, Missouri, with Governor Mike Kehoe and partners present. The GMP facility will produce Eye90 microspheres for liver cancer treatment, with completion in 2027 and commissioning in 2028.EntrevestorEntrevestorBioNova announced the eight semifinalists for its 10th annual BioInnovation Challenge, which will feature virtual pitches at the BioPort 2020 conference on November 3. The winning company will receive a $25,000 grant and $30,000 in in-kind services, while all finalists receive business training from Linda Plano. This competition has seen about 50 participants since its inception, with past winners like ABK BioMedical successfully raising significant funding.BioProcess InternationalABK Biomedical opens Missouri plant for Eye90 microspheresABK Biomedical has partnered with COR Development to construct a commercial manufacturing plant in Ashland, Missouri for its Eye90 microsphere technology used in liver cancer treatment. The facility will leverage proximity to the University of Missouri Research Reactor (MURR) for irradiation services and is expected to create 10–15 initial jobs upon completion in approximately 18 months.PR NewswireABK Biomedical and COR Development Partner to Establish Long-Term Commercial Manufacturing Facility in Ashland, MissouriABK Biomedical and COR Development have announced a strategic partnership to develop a GMP manufacturing facility in Ashland, Missouri, dedicated to commercial-scale production of Eye90 microspheres, an FDA-designated breakthrough technology in development for liver cancer treatment. The facility, to be built in Cartwright Business Park and overseen by Coil Construction, will leverage proximity to the University of Missouri Research Reactor (MURR), the only domestic producer of yttrium-90 radioisotope, providing a time-sensitive supply chain advantage. The project is expected to create high-tech jobs in the Columbia area and position Missouri as a hub for nuclear medicine and biotechnology.MorningstarABK Biomedical and COR Development Partner to Establish Long-Term Commercial Manufacturing Facility in Ashland, MissouriABK Biomedical and COR Development have announced a strategic partnership to develop a state-of-the-art GMP manufacturing facility in Ashland, Missouri at Cartwright Business Park. The facility will produce Eye90 microspheres, ABK's FDA-designated breakthrough technology for liver cancer treatment, with construction overseen by Coil Construction and proximity to the University of Missouri Research Reactor for Y-90 radioisotope supply. The project is expected to bring high-tech jobs to the Columbia area and strengthen Missouri's position as a hub for nuclear medicine and biotechnology.PR NewswireABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer TherapyABK Biomedical and the University of Missouri Research Reactor (MURR) have signed a long-term partnership agreement naming MURR as the primary irradiation partner for Eye90 microspheres, an advanced Yttrium-90 radioembolization therapy for liver cancer. The agreement formalizes seven years of collaboration and secures a reliable, scalable production partner as ABK transitions from clinical development to commercialization. MURR is currently the only location in the United States producing Y-90 for clinical and commercial use, and the partnership aims to advance medical innovation and expand global patient access to novel cancer therapies.BioSpaceABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer TherapyABK Biomedical and the University of Missouri Research Reactor (MURR) have signed a long-term agreement establishing MURR as the primary irradiation partner for Eye90 microspheres, an advanced Yttrium-90 radioembolization therapy for liver cancer treatment. The partnership builds on seven years of collaboration and supports the fully-enrolled Route90 FDA IDE clinical trial for hepatocellular carcinoma as ABK transitions from clinical development toward commercialization. The agreement secures a reliable and scalable production partner while positioning Missouri as a global leader in nuclear medicine and medical isotope production.PR NewswireABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver CancerABK Biomedical has completed patient enrollment in its ROUTE90 pivotal Phase III FDA IDE study evaluating Eye90 microspheres for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The study enrolled 120 patients across international centers and is described as the largest prospective FDA IDE trial conducted for Y90 radioembolization treatment of HCC, with co-principal investigators from UPMC and HCA Healthcare Sarah Cannon Cancer Network leading the study. The company now plans to submit its Premarket Approval (PMA) application to the FDA for regulatory approval, representing a significant milestone toward commercialization of the device.BioSpaceABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver CancerABK Biomedical announced completion of patient enrollment in its ROUTE90 pivotal FDA Investigational Device Exemption study evaluating Eye90 microspheres for treating unresectable hepatocellular carcinoma, the most common form of primary liver cancer. The international, prospective Phase III study enrolled 120 patients with co-primary endpoints of Overall Response Rate and Duration of Response, with 1-year follow-up post-treatment. The company, headquartered in Halifax, Nova Scotia, plans to submit a Premarket Approval application to the FDA following completion of patient follow-up.